A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluation
- DOI
- 10.1016/j.nucmedbio.2025.109042
- Published
- 2025-07
- Container
- Nuclear Medicine and Biology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.nucmedbio.2025.109042,
title = {A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluation},
author = {Caroline Foxton and Bart Cornelissen and Edward O'Neill and Bradley Waldron and Freja Pretzmann and Rikke Veggerby Grønlund and Mathias Wikke Hallund and Daniel J. Stevens},
year = {2025},
journal = {Nuclear Medicine and Biology},
doi = {10.1016/j.nucmedbio.2025.109042},
url = {https://doi.org/10.1016/j.nucmedbio.2025.109042}
}RIS
TY - JOUR TI - A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluation AU - Caroline Foxton AU - Bart Cornelissen AU - Edward O'Neill AU - Bradley Waldron AU - Freja Pretzmann AU - Rikke Veggerby Grønlund AU - Mathias Wikke Hallund AU - Daniel J. Stevens PY - 2025 JO - Nuclear Medicine and Biology DO - 10.1016/j.nucmedbio.2025.109042 UR - https://doi.org/10.1016/j.nucmedbio.2025.109042 ER -
APA
Foxton, C., Cornelissen, B., O'Neill, E., Waldron, B., Pretzmann, F., Grønlund, R. V., Hallund, M. W., & Stevens, D. J. (2025). A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluation. Nuclear Medicine and Biology. https://doi.org/10.1016/j.nucmedbio.2025.109042
Source records
- crossref · retrieved 2026-09-26T17:36:51.495Z